StockGuide AI
Track Stocks
EN RU ES
Ligand Pharmaceuticals

Ligand Pharmaceuticals

Price: 248.24

Company and Business Model

Ligand Pharmaceuticals is a biotechnology company focused on developing and commercializing technologies that enhance drug discovery and development. Its core products include a range of proprietary technologies and partnered programs that facilitate the creation of therapeutics across various disease areas. Major business segments include royalty revenue from partnered products and licensing agreements. The primary revenue sources stem from collaborations with pharmaceutical companies and royalties from sales of drugs utilizing Ligand's technologies.

Investment Profile

The investment profile of Ligand Pharmaceuticals is more aligned with value investors, given its current market position and revenue trends. The stock may appeal to those seeking potential long-term appreciation, although recent performance indicates challenges. Investors should consider the company's volatility and risk factors when evaluating their investment horizon.

Official website

Fundamental metrics (experimental)

EPS (TTM) — earnings per share for the last 12 months, $
7.84 OK
Revenue QoQ — quarter-over-quarter revenue growth
-13.3% ↓
EPS surprise
-11.4% worse than expected
20d volatility
1.8% stable
FMP / FinFeed data updated: 2026-06-11
Reco: Hold Potential: 65 Risk: 62 Updated: 2026-06-11 05:38
How recommendation works
Why AI thinks so:
Strong price momentum, but declining revenue raises concerns.

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
AI recommendation changes
Date Before After Reason
2026-05-24 02:44 Sell Hold Weak fundamentals and high risk limit upside potential.
2026-05-16 02:46 Hold Sell Weak fundamentals and negative momentum raise concerns.
2026-05-08 15:20 — Hold Weak fundamentals and negative momentum raise concerns.
Analyst forecasts
Date Analyst Action Target Price Then
2026-04-30 10:09 H.C. Wainwright Target Raised 243 → 289 224.86
2026-04-28 11:36 RBC Capital Target Raised 235 → 252 241.79
2026-04-27 18:05 Stifel Nicolaus Target Raised 230 → 255 241.79